Loading organizations...
§ Private Profile · Cambridge, MA, USA
Biotech company developing first-in-class ocular medicines, using AAV gene therapies for blinding eye diseases such as dry AMD.
Cirrus Therapeutics is a Cambridge, Massachusetts-based biotechnology company that develops adeno-associated virus gene therapies to treat blinding eye diseases, focusing primarily on dry age-related macular degeneration. The enterprise originally spun out of retina and ocular immunology research conducted at the University of Bristol before formally launching its operations from The Engine incubator. Operating as a venture-backed pharmaceutical developer, the organization focuses on creating targeted ocular medicines for patient populations currently lacking effective long-term treatment options. To support its preclinical development pipeline and advance its proprietary genetic medicines toward commercialization, the firm has raised $11 million in initial seed funding. The executive leadership team brings specialized expertise in genetic engineering, drawing on prior professional experience from the George Church laboratory and Ally Therapeutics. Cirrus Therapeutics was founded in 2023 by Ying Kai Chan and Andrew Dick.
Cirrus Therapeutics has raised $11.0M across 1 funding round.
Cirrus Therapeutics has raised $11.0M in total across 1 funding round.
Cirrus Therapeutics has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 2, 2025 | $11M Seed | Clavystbio | Alexandra Cantley, Polaris Partners, Seeds Capital | Announced |
Cirrus Therapeutics has raised $11.0M in total across 1 funding round.
Cirrus Therapeutics's investors include ClavystBio, Alexandra Cantley, Polaris Partners, SEEDS Capital.